Skip to content

Fit4Chemo: feasibility and effectiveness of a multimodal revalidation program in patients with stage 3 colon carcinoma prior and during adjuvant chemotherapy

Fit4Chemo: feasibility and effectiveness of a multimodal revalidation program in patients with stage 3 colon carcinoma prior and during adjuvant chemotherapy - Fit4Chemo

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON54938
Enrollment
20
Registered
2020-10-29
Start date
2021-01-07
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bowel cancer colon carcinoma

Interventions

None listed

Sponsors

Heelkunde
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients (>18 years) with stage 3 colon carcinoma eligible for treatment with adjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Patients

Design outcomes

Primary

MeasureTime frame
Feasibility will be evaluated by: - safety: occurance of side effects/complications as a result of the intervention - adherence of the intervention by patients - fidelity of the intervention by fysiotherapists - satisfaction of both patients as fysiotherapists - practicability of the intervention - implementability of the intervention Potential effectiveness will be evaluated by 1. Self-reported functional recovery: difference in physical activity between start and end of revalidation program 2. Observed functional recovery: difference between start and end of revalidation program in quality of life, performance status, fatigue, short physical perforamce battery, maximal exertion, muscle strength, anthropometry, fat-free body mass, nutritional status 3. Time between surgical procedure and start of adjuvant chemotherapy 4. Side effects of adjuvant chemotherapy 5. Compliance of adjuvant chemotherapy

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)